Takeda Pharmaceutical Co. Ltd. spinout Phathom Pharmaceuticals, Inc. got its first US Food and Drug Administration approval, for the acid-blocker vonoprazan, on 3 May, which could be a precursor to future approvals in gastroesophageal reflux disorder (GERD) indications that may give the drug blockbuster sales in the US. The initial approval is for Voquezna Triple Pak and Voquezna Dual Pak, for treating Heliobacter pylori infections, consisting of vonoprazan packaged with generic antibiotics.
Phathom’s First Approval Of Voquezna Expected To Lay Ground For Larger Indications
The Takeda spinout got FDA approval of its acid blocker as combination therapy for H. pylori infections, but the bigger opportunities await in erosive esophagitis and non-erosive reflux disorder.
